Cisen Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 18.00 Cr
- Paid Up Capital ₹ 17.68 Cr
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 16.58%
- Profit Growth -2.20%
- Ebitda -1.98%
- Net Worth 4.59%
- Total Assets -3.72%
About Cisen Pharmaceuticals India
Cisen Pharmaceuticals India Private Limited (CPIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 20 September 2018 (Six years and five months 8 days old ). Its registered office is in South Goa, Goa, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 18.00 Cr and a paid-up capital of Rs 17.68 Cr, as per Ministry of Corporate Affairs (MCA) records.
Xiulian Lu, Mrinal Khatua, and Anuva Khatua serve as directors at the Company.
Company Details
- Location
South Goa, Goa, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U73200GA2018FTC013696
- Company No.
013696
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
20 Sep 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Goa
Industry
Who are the key members and board of directors at Cisen Pharmaceuticals India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Xiulian Lu  | Director | 20-Sep-2018 | Current |
Mrinal Khatua  | Director | 20-Sep-2018 | Current |
| Anuva Khatua | Director | 20-Sep-2018 | Current |
Financial Performance of Cisen Pharmaceuticals India.
Cisen Pharmaceuticals India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.58% increase. The company also saw a slight decrease in profitability, with a 2.2% decrease in profit. The company's net worth moved up by a moderate rise of 4.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cisen Pharmaceuticals India?
In 2023, Cisen Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cisen Pharmaceuticals India?
Cisen Pharmaceuticals India has a workforce of 24 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cisen Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cisen Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.